IP Library Granted Patent US 8,962,680
Granted Patent B2
US 8,962,680 · App. 13/285,397 · Granted Feb 24, 2015

Methods and compositions for treating HIV-associated diarrhea

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,962,680
App. No.
13/285,397
Granted
Feb 24, 2015
Kind
B2
Abstract

Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.

Claims (31)

1. A method of treating stool consistency in an HIV positive subject, comprising:

administering about 250 mg of crofelemer per day to the HIV positive subject.

2. A method of improving stool consistency in an HIV positive subject, comprising:

administering about 250 mg of crofelemer per day to the HIV positive subject.

3. A method of alleviating watery diarrhea in an HIV positive subject, comprising:

administering about 250 mg of crofelemer per day to the HIV positive subject.

4. A method of decreasing the number of bowel movements per day in an HIV positive subject, comprising:

administering about 250 mg of crofelemer per day to the HIV positive subject.

5. The method of any one of claim 1 , 2 , 3 or 4 wherein the administering is from between about 1 month and about 6 months.

6. The method of any one of claim 1 , 2 , 3 or 4 wherein the administering is from between about 3 days and 6 months.

7. The method of any one of claim 1 , 2 , 3 or 4 wherein improvement of symptoms begins on day 3.

8. The method of any one of claim 1 , 2 , 3 or 4 wherein improvement of symptoms increases with a longer duration of administration after day 3.

9. The method of any one of claim 1 , 2 , 3 or 4 wherein the subject is of Caucasian or Hispanic descent.

10. The method of any one of claim 1 , 2 , 3 or 4 wherein the crofelemer is administered for at least 8 days.

11. The method of any one of claim 1 , 2 , 3 or 4 wherein the crofelemer is administered from between 8 days and 24 weeks.

12. The method of any one of claim 1 , 2 , 3 or 4 wherein the administering is for about 6 months.

13. The method of any one of claim 1 , 2 , 3 or 4 wherein the administering is about 6 months or longer.

14. The method of any one of claim 1 , 2 , 3 or 4 wherein the administering is for the duration of the HIV infection.

15. The method of any one of claim 1 , 2 , 3 or 4 wherein the response to treatment increases after the crofelemer has been administered for longer than 4 months.

16. The method of any one of claim 1 , 2 , 3 or 4 wherein the subject is considered treated if the subject demonstrates one or more of: a decrease in the number of bowel movements per day, a decrease in the number of watery bowel movements per day, an improvement in the daily abdominal score for pain or discomfort, an improvement in the score for daily stool consistency, a decrease in stool consistency, a decrease in the number of days per week that subjects experienced urgency, a decrease in the number of days per week that subjects experienced fecal incontinence, or a decrease in the unscheduled visit for a significant worsening of diarrhea.

17. The method of claim 1 , wherein subject is considered treated if the subject demonstrates an improvement in the score for daily stool consistency.

18. The method of claim 2 , wherein subject is considered treated if the subject demonstrates a decrease in stool consistency.

19. The method of claim 3 , wherein subject is considered treated if the subject demonstrates a decrease in the number of watery bowel movements per day.

20. The method of claim 4 , wherein subject is considered treated if the subject demonstrates a decrease in the number of bowel movements per day.

21. The method of claim 16 , wherein symptoms increased or decreased are measured from a baseline.

22. A method of decreasing the number of days per week a subject experiences fecal incontinence associated with HIV associated diarrhea or HAART associated diarrhea, comprising: administering about 250 mg of crofelemer per day to the subject experiencing fecal incontinence associated with HIV or HAART.

23. The method of claim 1 , comprising administering about 125 mg of crofelemer to the subject two times per day.

24. The method of claim 2 , comprising administering about 125 mg of crofelemer to the subject two times per day.

25. The method of claim 3 , comprising administering about 125 mg of crofelemer to the subject two times per day.

26. The method of claim 4 , comprising administering about 125 mg of crofelemer to the subject two times per day.

27. The method of claim 22 , comprising administering about 125 mg of crofelemer to the subject two times per day.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Jan 9, 2026
From: KINGDON CAPITAL MANAGEMENT, L.L.C.
To: NAPO PHARMACEUTICALS, INC.
Reel/Frame 073427/0228 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST Recorded Apr 10, 2018
From: HERCULES CAPITAL, INC.
To: JAGUAR HEALTH, INC.
Reel/Frame 045496/0039 →
SECURITY INTEREST Recorded Nov 22, 2017
From: NAPO PHARMACEUTICALS, INC.
To: KINGDON CAPITAL MANAGEMENT, L.L.C.
Reel/Frame 044497/0954 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2016
From: SALIX PHARMACEUTICALS, INC.
To: NAPO PHARMACEUTICALS, INC.
Reel/Frame 038168/0355 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2016
From: SALIX PHARMACEUTICALS, LTD.
To: SALIX PHARMACEUTICALS, INC.
Reel/Frame 037910/0987 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 12, 2016
From: JAGUAR ANIMAL HEALTH, INC.
To: HERCULES TECHNOLGY GROWTH CAPITAL, INC., AS AGENT
Reel/Frame 037809/0161 →
SECURITY AGREEMENT Recorded Apr 2, 2015
From: GLYCYX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 035364/0396 →
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2015
From: JEFFERIES FINANCE LLC
To: SALIX PHARMACEUTICALS, LTD.
Reel/Frame 035353/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2014
From: FORBES, WILLIAM; BORTEY, ENOCH
To: SALIX PHARMACEUTICALS, LTD
Reel/Frame 031913/0128 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2014
From: KING, STEVEN; CHATURVEDI, PRAVIN
To: NAPO PHARMACEUTICALS, INC.
Reel/Frame 031913/0266 →
SECURITY AGREEMENT Recorded Jan 2, 2014
From: SALIX PHARMACEUTICALS, LTD.
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 031896/0752 →